The Conundrum of TRAE Management Across Immunotherapies in NSCLC: A Community Oncology Nurse Approach

Release Date November 13, 2026
Expiration Date November 13, 2027
Format Webcast
CE 1.0 contact hour
 

Acknowledgement

This activity is provided by Talem Health and ACCESS Oncology.


This activity is supported by an independent educational grant from Regeneron Pharmaceuticals, Inc.

Credit Available

  • Nurses — 1.0 Contact Hour (0.75 contact hour of pharmacotherapy credit)

Target Audience

This activity is designed specifically for oncology nurses, nurse practitioners, and other nursing professionals who provide cancer care in community and non-academic settings. 

Program Overview

The treatment paradigm for non-small cell lung cancer (NSCLC) has shifted over the past decade with the development and approval of immune checkpoint inhibitors, which have improved outcomes for patients without actionable driver alterations. However, immunotherapy and combination immunotherapy approaches are associated with unique toxicity profiles, underscoring the need for additional education to equip oncology nurses, particularly those serving geographically diverse populations, with the knowledge and skills to effectively manage treatment-related adverse events. In this on-demand CE activity, expert faculty will discuss strategies to enhance the prompt identification and management of immune-related adverse events in patients with NSCLC. The program will also explore approaches to strengthen patient communication and education, promoting greater understanding, recognition, and reporting of adverse events related to immunotherapy.

The content for this enduring activity was recorded during a live webinar on October 2, 2026.

Learning Objectives

Upon completion of this activity, participants should be better able to:  

  • Identify clinical features of treatment-related adverse events associated with immune checkpoint inhibitors to support timely recognition 
  • Implement evidence-based management strategies for treatment-related adverse events associated with immunotherapy in patients with NSCLC   
  • Apply patient-centered communication and education strategies to support patient understanding and self-reporting of adverse events

Faculty

Christine L. Long, DNP, APRN, FNP-C, AOCNP
Nurse Practitioner, APP Virtual Services
Texas Oncology
Austin, TX

 

Lance F. Ortega, MBA, BSN, RN, OCN 
Executive Director, Clinical Operations  
Texas Oncology 
Dallas-Fort Worth, TX 

Joint Accreditation Statement

In support of improving patient care, Talem Health is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.


 

Credit Designation Statement

Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour. Designated for 0.75 contact hour of pharmacotherapy credit for Advanced Practice Registered Nurses.

Disclosure of Conflicts of Interest

Talem Health adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers, or others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All identified conflicts of interest are thoroughly vetted and mitigated according to Talem Health policy. Talem Health is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

Faculty

Christine L. Long, DNP, APRN, FNP-C, AOCNP, has no relevant financial relationship(s) with ineligible companies to disclose.
 
Lance F. Ortega, MBA, BSN, RN, OCN, has no relevant financial relationship(s) with ineligible companies to disclose. 

Planners, Managers, and Reviewer 
None of the Talem Health staff (planners, managers, or reviewer) for this educational activity have relevant financial relationship(s) to disclose with ineligible companies. 

Instructions for Participation and Credit

This activity is offered at no cost to participants. To receive CE credit, participants must: 

  1. Read the CE information, including learning objectives and disclosure statements. 
  2. Complete the pre-test. 
  3. View the online activity. 
  4. Complete the post-test and evaluation form. 

A post-test score of 67% or higher is required to obtain credit. Your certificate will be made available for immediate download. 

Course Viewing Requirements 

Supported Browsers: 
Desktop/laptop: Newest and last prior version of Google Chrome, Firefox, Safari, and Microsoft Edge
Mobile devices: Newest and last prior version of Safari and Google Chrome

Supported Phones & Tablets: 
All devices

Disclosure of Unlabeled Use 

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.  

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.  

©ACCESS Oncology, a division of Talem Health, LLC. All Rights Reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Talem Health, LLC is prohibited. 

Media 

Internet activity 

Fee Information 

There is no fee for this educational activity. 

Contact Information 

For questions about this activity, please contact ACCESS Oncology (a division of Talem Health) at 800-913-9370 or cme@accessoncologyce.com.